Antagonism of AMPA receptors produces anxiolytic-like behavior in rodents: Effects of GYKI 52466 and its novel analogues

Gábor L. Kapus, István Gacsályi, Miklos Vegh, Hajnalka Kompagne, Endre Hegedus, Csilla Leveleki, L. Hársing, József Barkóczy, András Bilkei-Gorzó, György Lévay

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Rationale: Although emerging number of data supports the role of glutamate receptors and the potential of their antagonists in anxiety disorders, the involvement of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)/kainate receptors in anxiety is less well characterized. Objective: To evaluate the anxiolytic potential of 2,3-benzodiazepine (2,3BDZ) type AMPA receptor antagonists in various models of anxiety. Materials and methods: Whole-cell currents, hippocampal field potentials, elevated plus maze (EPM), meta-chlorophenylpiperazine (mCPP)-induced anxiety model, Vogel test in rats and light-dark test (LD) in mice were used to determine AMPA/kainite receptor properties and anxiolytic-like activity of a series of 2,3BDZ-type compounds. Results: The reference compound GYKI 52466 was proved active in two anxiety models in non-sedative doses: minimal effective dose (MED) was especially low in EPM (0.01 mg/kg) GYKI 53405 and GYKI 53655 showed anxiolytic-like activity in two tests (EPM and mCPP). EGIS-8332 was active in EPM and LD while EGIS-9637 showed anxiolytic-like potency in EPM, mCPP and Vogel model. EGIS-10608 was the most effective compound among 2,3BDZs tested in EPM and Vogel models (MEDs are 0.01 and 2.5 mg/kg, respectively). 2,3BDZs were active in anxiety models at doses lower than those produced sedative effects. NBQX showed anxiolytic-like activity in EPM only (3 mg/kg). Conclusions: The results show that non-competitive AMPA receptor antagonists can profoundly block anxiety-like behavior in rodents independently from their motor depressant activity. However, the sedative properties at higher doses might limit their therapeutic utility as new anxiolytic drugs.

Original languageEnglish
Pages (from-to)231-241
Number of pages11
JournalPsychopharmacology
Volume198
Issue number2
DOIs
Publication statusPublished - Jun 2008

Fingerprint

AMPA Receptors
Anti-Anxiety Agents
Rodentia
Anxiety
GYKI 53655
Hypnotics and Sedatives
GYKI 53405
Kainic Acid Receptors
Light
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid
Glutamate Receptors
GABA-A Receptors
Anxiety Disorders
Benzodiazepines
GYKI 52466
Motor Activity
Pharmaceutical Preparations
1-(3-chlorophenyl)piperazine

Keywords

  • AMPA antagonist
  • Anxiolytic
  • EGIS-10608
  • EGIS-8332
  • Glutamate
  • GYKI 52466
  • Light-dark
  • Plus-maze
  • Vogel conflict

ASJC Scopus subject areas

  • Pharmacology

Cite this

Kapus, G. L., Gacsályi, I., Vegh, M., Kompagne, H., Hegedus, E., Leveleki, C., ... Lévay, G. (2008). Antagonism of AMPA receptors produces anxiolytic-like behavior in rodents: Effects of GYKI 52466 and its novel analogues. Psychopharmacology, 198(2), 231-241. https://doi.org/10.1007/s00213-008-1121-z

Antagonism of AMPA receptors produces anxiolytic-like behavior in rodents : Effects of GYKI 52466 and its novel analogues. / Kapus, Gábor L.; Gacsályi, István; Vegh, Miklos; Kompagne, Hajnalka; Hegedus, Endre; Leveleki, Csilla; Hársing, L.; Barkóczy, József; Bilkei-Gorzó, András; Lévay, György.

In: Psychopharmacology, Vol. 198, No. 2, 06.2008, p. 231-241.

Research output: Contribution to journalArticle

Kapus, GL, Gacsályi, I, Vegh, M, Kompagne, H, Hegedus, E, Leveleki, C, Hársing, L, Barkóczy, J, Bilkei-Gorzó, A & Lévay, G 2008, 'Antagonism of AMPA receptors produces anxiolytic-like behavior in rodents: Effects of GYKI 52466 and its novel analogues', Psychopharmacology, vol. 198, no. 2, pp. 231-241. https://doi.org/10.1007/s00213-008-1121-z
Kapus, Gábor L. ; Gacsályi, István ; Vegh, Miklos ; Kompagne, Hajnalka ; Hegedus, Endre ; Leveleki, Csilla ; Hársing, L. ; Barkóczy, József ; Bilkei-Gorzó, András ; Lévay, György. / Antagonism of AMPA receptors produces anxiolytic-like behavior in rodents : Effects of GYKI 52466 and its novel analogues. In: Psychopharmacology. 2008 ; Vol. 198, No. 2. pp. 231-241.
@article{a5728343ae4d441a9a66156c924cfe88,
title = "Antagonism of AMPA receptors produces anxiolytic-like behavior in rodents: Effects of GYKI 52466 and its novel analogues",
abstract = "Rationale: Although emerging number of data supports the role of glutamate receptors and the potential of their antagonists in anxiety disorders, the involvement of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)/kainate receptors in anxiety is less well characterized. Objective: To evaluate the anxiolytic potential of 2,3-benzodiazepine (2,3BDZ) type AMPA receptor antagonists in various models of anxiety. Materials and methods: Whole-cell currents, hippocampal field potentials, elevated plus maze (EPM), meta-chlorophenylpiperazine (mCPP)-induced anxiety model, Vogel test in rats and light-dark test (LD) in mice were used to determine AMPA/kainite receptor properties and anxiolytic-like activity of a series of 2,3BDZ-type compounds. Results: The reference compound GYKI 52466 was proved active in two anxiety models in non-sedative doses: minimal effective dose (MED) was especially low in EPM (0.01 mg/kg) GYKI 53405 and GYKI 53655 showed anxiolytic-like activity in two tests (EPM and mCPP). EGIS-8332 was active in EPM and LD while EGIS-9637 showed anxiolytic-like potency in EPM, mCPP and Vogel model. EGIS-10608 was the most effective compound among 2,3BDZs tested in EPM and Vogel models (MEDs are 0.01 and 2.5 mg/kg, respectively). 2,3BDZs were active in anxiety models at doses lower than those produced sedative effects. NBQX showed anxiolytic-like activity in EPM only (3 mg/kg). Conclusions: The results show that non-competitive AMPA receptor antagonists can profoundly block anxiety-like behavior in rodents independently from their motor depressant activity. However, the sedative properties at higher doses might limit their therapeutic utility as new anxiolytic drugs.",
keywords = "AMPA antagonist, Anxiolytic, EGIS-10608, EGIS-8332, Glutamate, GYKI 52466, Light-dark, Plus-maze, Vogel conflict",
author = "Kapus, {G{\'a}bor L.} and Istv{\'a}n Gacs{\'a}lyi and Miklos Vegh and Hajnalka Kompagne and Endre Hegedus and Csilla Leveleki and L. H{\'a}rsing and J{\'o}zsef Bark{\'o}czy and Andr{\'a}s Bilkei-Gorz{\'o} and Gy{\"o}rgy L{\'e}vay",
year = "2008",
month = "6",
doi = "10.1007/s00213-008-1121-z",
language = "English",
volume = "198",
pages = "231--241",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Antagonism of AMPA receptors produces anxiolytic-like behavior in rodents

T2 - Effects of GYKI 52466 and its novel analogues

AU - Kapus, Gábor L.

AU - Gacsályi, István

AU - Vegh, Miklos

AU - Kompagne, Hajnalka

AU - Hegedus, Endre

AU - Leveleki, Csilla

AU - Hársing, L.

AU - Barkóczy, József

AU - Bilkei-Gorzó, András

AU - Lévay, György

PY - 2008/6

Y1 - 2008/6

N2 - Rationale: Although emerging number of data supports the role of glutamate receptors and the potential of their antagonists in anxiety disorders, the involvement of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)/kainate receptors in anxiety is less well characterized. Objective: To evaluate the anxiolytic potential of 2,3-benzodiazepine (2,3BDZ) type AMPA receptor antagonists in various models of anxiety. Materials and methods: Whole-cell currents, hippocampal field potentials, elevated plus maze (EPM), meta-chlorophenylpiperazine (mCPP)-induced anxiety model, Vogel test in rats and light-dark test (LD) in mice were used to determine AMPA/kainite receptor properties and anxiolytic-like activity of a series of 2,3BDZ-type compounds. Results: The reference compound GYKI 52466 was proved active in two anxiety models in non-sedative doses: minimal effective dose (MED) was especially low in EPM (0.01 mg/kg) GYKI 53405 and GYKI 53655 showed anxiolytic-like activity in two tests (EPM and mCPP). EGIS-8332 was active in EPM and LD while EGIS-9637 showed anxiolytic-like potency in EPM, mCPP and Vogel model. EGIS-10608 was the most effective compound among 2,3BDZs tested in EPM and Vogel models (MEDs are 0.01 and 2.5 mg/kg, respectively). 2,3BDZs were active in anxiety models at doses lower than those produced sedative effects. NBQX showed anxiolytic-like activity in EPM only (3 mg/kg). Conclusions: The results show that non-competitive AMPA receptor antagonists can profoundly block anxiety-like behavior in rodents independently from their motor depressant activity. However, the sedative properties at higher doses might limit their therapeutic utility as new anxiolytic drugs.

AB - Rationale: Although emerging number of data supports the role of glutamate receptors and the potential of their antagonists in anxiety disorders, the involvement of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)/kainate receptors in anxiety is less well characterized. Objective: To evaluate the anxiolytic potential of 2,3-benzodiazepine (2,3BDZ) type AMPA receptor antagonists in various models of anxiety. Materials and methods: Whole-cell currents, hippocampal field potentials, elevated plus maze (EPM), meta-chlorophenylpiperazine (mCPP)-induced anxiety model, Vogel test in rats and light-dark test (LD) in mice were used to determine AMPA/kainite receptor properties and anxiolytic-like activity of a series of 2,3BDZ-type compounds. Results: The reference compound GYKI 52466 was proved active in two anxiety models in non-sedative doses: minimal effective dose (MED) was especially low in EPM (0.01 mg/kg) GYKI 53405 and GYKI 53655 showed anxiolytic-like activity in two tests (EPM and mCPP). EGIS-8332 was active in EPM and LD while EGIS-9637 showed anxiolytic-like potency in EPM, mCPP and Vogel model. EGIS-10608 was the most effective compound among 2,3BDZs tested in EPM and Vogel models (MEDs are 0.01 and 2.5 mg/kg, respectively). 2,3BDZs were active in anxiety models at doses lower than those produced sedative effects. NBQX showed anxiolytic-like activity in EPM only (3 mg/kg). Conclusions: The results show that non-competitive AMPA receptor antagonists can profoundly block anxiety-like behavior in rodents independently from their motor depressant activity. However, the sedative properties at higher doses might limit their therapeutic utility as new anxiolytic drugs.

KW - AMPA antagonist

KW - Anxiolytic

KW - EGIS-10608

KW - EGIS-8332

KW - Glutamate

KW - GYKI 52466

KW - Light-dark

KW - Plus-maze

KW - Vogel conflict

UR - http://www.scopus.com/inward/record.url?scp=43049094347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43049094347&partnerID=8YFLogxK

U2 - 10.1007/s00213-008-1121-z

DO - 10.1007/s00213-008-1121-z

M3 - Article

C2 - 18363046

AN - SCOPUS:43049094347

VL - 198

SP - 231

EP - 241

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 2

ER -